19 results match your criteria: "Maastricht University Medical Center and CAPHRI Research Institute[Affiliation]"
Consensus on the definitions and descriptions of the domains of the OMERACT Core Outcome Set for shared decision making interventions in rheumatology trials.
Semin Arthritis Rheum
April 2024
School of Rehabilitation Sciences, Faculty of Health Sciences, University of Ottawa; Department of Pediatrics, Faculty of Medicine, University of Ottawa; Affiliate scientist, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada; Institut du savoir Montfort, Ottawa, Canada. Electronic address:
Objective: To gain consensus on the definitions and descriptions of the domains of the Outcome Measures in Rheumatology (OMERACT) core domain set for rheumatology trials evaluating shared decision making (SDM) interventions.
Methods: Following the OMERACT Handbook methods, our Working Group (WG), comprised of 90 members, including 17 patient research partners (PRPs) and 73 clinicians and researchers, had six virtual meetings in addition to email exchanges to develop draft definitions and descriptions. The WG then conducted an international survey of its members to gain consensus on the definitions and descriptions.
OMERACT Core outcome measurement set for shared decision making in rheumatic and musculoskeletal conditions: a scoping review to identify candidate instruments.
Semin Arthritis Rheum
April 2024
Faculty of Medicine and Health Sciences, School of Rehabilitation, Research Centre of the CHUS, CIUSSS de l'Estrie-CHUS, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke, Quebec J1H 5N4, Canada. Electronic address:
Objectives: Shared decision making (SDM) is a central tenet in rheumatic and musculoskeletal care. The lack of standardization regarding SDM instruments and outcomes in clinical trials threatens the comparative effectiveness of interventions. The Outcome Measures in Rheumatology (OMERACT) SDM Working Group is developing a Core Outcome Set for trials of SDM interventions in rheumatology and musculoskeletal health.
View Article and Find Full Text PDFEndorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach.
Semin Arthritis Rheum
June 2021
Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Objective: To gain consensus on the Outcome Measures in Rheumatology (OMERACT) core domain set for rheumatology trials of shared decision making (SDM) interventions.
Methods: The process followed the OMERACT Filter 2.1 methodology, and used consensus-building methods, with patients involved since the inception.
Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial.
Arthritis Care Res (Hoboken)
March 2022
Ruhr-University Bochum, Bochum, Germany, and Osaka City University Graduate School of Medicine, Osaka, Japan.
Article Synopsis
- The COAST-X trial assessed the impact of ixekizumab on functioning and health in patients with active nonradiographic axial spondyloarthritis over 52 weeks, comparing it to placebo.
- Ixekizumab treatment led to significant improvements in self-reported health scores, particularly in physical functioning, pain, and overall health status, with better results in patients receiving treatment every 2 weeks.
- Patients on ixekizumab reported notable enhancements in quality of life measures (EQ-5D-5L) compared to placebo, showing sustained benefits by week 52.
Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider.
RMD Open
December 2018
Department of Rheumatology, Leiden University Medical Centre, Leiden, and Zuyderland Medical Center, Heerlen, The Netherlands.
Objective: To summarise the available information on physician workforce modelling, to develop a rheumatology workforce prediction risk of bias tool and to apply it to existing studies in rheumatology.
Methods: A systematic literature review (SLR) was performed in key electronic databases (1946-2017) comprising an update of an SLR in rheumatology and a hierarchical SLR in other medical fields. Data on the type of workforce prediction models and the factors considered in the models were extracted.
Deriving common comorbidity indices from the MedDRA classification and exploring their performance on key outcomes in patients with rheumatoid arthritis.
Rheumatology (Oxford)
March 2018
Rheumatology, Maastricht University Medical Center and CAPHRI Research Institute, Maastricht, the Netherlands.
Objective: To develop algorithms for calculating the Rheumatic Diseases Comorbidity Index (RDCI), Charlson-Deyo Index (CDI) and Functional Comorbidity Index (FCI) from the Medical Dictionary for Regulatory Activities (MedDRA), and to assess how these MedDRA-derived indices predict clinical outcomes, utility and health resource utilization (HRU).
Methods: Two independent researchers linked the preferred terms of the MedDRA classification into the conditions included in the RDCI, the CDI and the FCI. Next, using data from the Norwegian Register-DMARD study (a register of patients with inflammatory joint diseases treated with DMARDs), the explanatory value of these indices was studied in models adjusted for age, gender and DAS28.
Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting.
J Rheumatol
October 2017
From the Children's Hospital of Eastern Ontario Research Institute, Ottawa; Department of Pediatrics and School of Rehabilitation Sciences, University of Ottawa, and Department of Epidemiology and Community Medicine, and Department of Medicine, Faculty of Medicine, University of Ottawa; School of Nursing, University of Ottawa; Integrated Knowledge Translation Network and University of Ottawa; Ottawa Hospital Research Institute, Centre for Practice-Changing Research and University of Ottawa; Bruyère Research Institute, Bruyère Continuing Care and School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Department of Epidemiology and Community Medicine, Faculty of Medicine, and Institute of Population Health, Centre for Global Health, University of Ottawa, Ottawa; Musculoskeletal Health and Outcomes Research, Li Ka Shing Knowledge Institute, St. Michael's Hospital; Institute for Work and Health, Institute Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario; Department of Physical Therapy, University of British Columbia; Arthritis Research Centre of Canada, Vancouver, British, Columbia; Department of Family Medicine and Emergency Medicine, Université Laval, Quebec City, Montreal, Canada; VA Portland Health Care System; Oregon Health and Science University, Portland, Oregon; Department of Internal Medicine, Yale University, New Haven, Connecticut; The Ohio State University, Columbus; Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Department of General Internal Medicine, Section of Rheumatology and Clinical Immunology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; School of Population and Global Health, University of Melbourne; Centre for Health Communication and Participation, School of Psychology and Public Health, La Trobe University, Melbourne; Western Sydney University and Faculty of Medicine, University of Sydney; Department of Medicine, University of Sydney, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; VU Medical Centre, Amsterdam; Department Psychology, Health and Technology, University of Twente, Enschede; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht University, Maastricht; Access to Medicine Foundation, Haarlem, the Netherlands; Sorbonne Universités, UPMC Univ Paris 06, GRC-08; Pitie-Salpétrière Hospital, AP-HP, Rheumatology Department, Paris, France; Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; Department of Internal Medicine II Rheumatology, Clinical Immunology, Osteology, Physical Therapy and Sports Medicine, Schlosspark-Klinik, Charité, University Medicine Berlin, Berlin, Germany; Rheumatology and Rehabilitation, Ain Shams University, Cairo, Egypt; King's College London, London, UK.
Objective: The aim of this Outcome Measures in Rheumatology (OMERACT) Working Group was to determine the core set of outcome domains and subdomains for measuring the effectiveness of shared decision-making (SDM) interventions in rheumatology clinical trials.
Methods: Following the OMERACT Filter 2.0, and based on a previous literature review of SDM outcome domains and a nominal group process at OMERACT 2014, (1) an online Delphi survey was conducted to gather feedback on the draft core set and refine its domains and subdomains, and (2) a workshop was held at the OMERACT 2016 meeting to gain consensus on the draft core set.
Social Role Participation in Patients With Ankylosing Spondylitis: A Cross-Sectional Comparison With Population Controls.
Arthritis Care Res (Hoboken)
December 2016
Annelies Boonen, MD, PhD, Maastricht University Medical Center and Caphri Research Institute, Maastricht University, Maastricht, The Netherlands.
Objective: Participation in social roles for persons with chronic disease is important for their quality of life, but interpretation of the data on participation is difficult in the absence of a benchmark. This study aimed to compare social role participation in patients with ankylosing spondylitis (AS) to population controls using the Social Role Participation Questionnaire (SRPQ).
Methods: There were 246 AS patients and 510 population controls who completed the SRPQ, which assesses participation in 11 roles (with scores ranging 1-5) across 4 dimensions (importance, satisfaction with performance, satisfaction with time, and physical difficulty), and additionally ranked their 3 most important roles.
Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD.
Rheumatology (Oxford)
July 2016
Rheumatology, Maastricht University Medical Center and CAPHRI Research Institute Maastricht University.
Objective: To explore whether age, gender or education influence the time until initiation of the first bDMARD in patients with RA.
Methods: Data from the Norwegian Register of DMARDs collected between 2000 and 2012 were used. Only DMARD-naïve patients with RA starting their first conventional synthetic DMARD were included in the analyses.
Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process.
J Rheumatol
November 2015
From the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, UK; Division of Rheumatology, University of Ottawa, Ottawa, Ontario, Canada; Department of Public Health Sciences, University of Iceland, Reykjavik, Iceland; Nuffield Department of Population Health (HSRU), University of Oxford, Oxford, UK; Department of Family Medicine and Community Health, and Division of Rheumatology and Department of Biostatistics and Epidemiology, University of Pennsylvania, and Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Departments of Epidemiology and Biostatistics; and Rheumatology, VU University Medical Center, Amsterdam, The Netherlands; Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, University Maastricht, Maastricht, The Netherlands; Vasculitis Foundation, Denver, Colorado, USA; Division of Biostatistics and Informatics, Department of Pediatrics, College of Medicine, University of South Florida, Tampa, Florida, USA; Vasculitis Clinical Research Consortium, and Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.J.C. Robson, MBBS, PhD, Clinical Lecturer in Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford; N. Milman, MD, FRCPC, Clinical Lecturer in Rheumatology, Division of Rheumatology, University of Ottawa; G. Tomasson, MD, Department of Public Health Sciences, University of Iceland; J. Dawson, MA, MSc, DPhil, University Research Lecturer and Senior Research Scientist, Nuffield Department of Population Health (HSRU), University of Oxford; P.F. Cronholm, MD, MSCE, FAAFP, Associate Professor, Department of Family Medicine and Community Health, University of Pennsylvania; K. Kellom, BA, Senior Research Coordinator, Department of Family Medicine and Community Health, University of Pennsylvania; J. Shea, PhD, Professor of Medici
Objective: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of linked multisystem life- and organ-threatening diseases. The Outcome Measures in Rheumatology (OMERACT) vasculitis working group has been at the forefront of outcome development in the field and has achieved OMERACT endorsement of a core set of outcomes for AAV. Patients with AAV report as important some manifestations of disease not routinely collected through physician-completed outcome tools; and they rate common manifestations differently from investigators.
View Article and Find Full Text PDFToward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures.
J Rheumatol
December 2015
From the Centre for Global Health, University of Ottawa, Ottawa, Ontario, Canada; University of Lorraine, EA 4360 Apemac, Nancy, France; Cabrini Institute and Monash University, Melbourne, Australia; Bruyère Research Institute, and the Institute of Population Health, University of Ottawa, Ottawa, Ontario, Canada; Faculty of Medicine, Nursing and Health Sciences, Monash University, Australia; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospitals, Bispebjerg and Frederiksberg, Denmark; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht University, Maastricht, The Netherlands; Quintiles Inc.; Division of Rheumatology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA; Children's Hospital of Eastern Ontario Research Institute, Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada; VU Medical Centre, Amsterdam, The Netherlands; University of California at San Francisco, San Francisco, California, USA; Faculty of Health and Applied Sciences, University of the West of England, Bristol, UK; Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Internal Medicine II Rheumatology, Clinical Immunology, Osteology, Physical Therapy and Sports Medicine, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Marmara, Faculty of Medicine, Department of Physical and Rehabilitation Medicine, Rheumatology Clinics, Istanbul, Turkey; Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama; Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Ottawa Hospital Research Institute, Ottawa; University Health Network (UHN)-Toronto Western Hospital, Toronto, Ontario
Objective: The goal of the Outcome Measures in Rheumatology (OMERACT) 12 (2014) equity working group was to determine whether and how comprehensibility of patient-reported outcome measures (PROM) should be assessed, to ensure suitability for people with low literacy and differing cultures.
Methods: The English, Dutch, French, and Turkish Health Assessment Questionnaires and English and French Osteoarthritis Knee and Hip Quality of Life questionnaires were evaluated by applying 3 readability formulas: Flesch Reading Ease, Flesch-Kincaid grade level, and Simple Measure of Gobbledygook; and a new tool, the Evaluative Linguistic Framework for Questionnaires, developed to assess text quality of questionnaires. We also considered a study assessing cross-cultural adaptation with/without back-translation and/or expert committee.
Development of a Draft Core Set of Domains for Measuring Shared Decision Making in Osteoarthritis: An OMERACT Working Group on Shared Decision Making.
J Rheumatol
December 2015
From the Children's Hospital of Eastern Ontario Research Institute and Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada; VA Portland Health Care System, and Oregon Health and Science University, Portland, Oregon, USA; Department of Internal Medicine, Yale University, New Haven, Connecticut, USA; Department of Physical Therapy, University of British Columbia and Arthritis Research Centre of Canada, Vancouver, British Columbia, Canada; School of Rehabilitation Sciences, University of Ottawa, Ottawa, Ontario, Canada; Rheumatic Diseases, University of Lorraine, Nancy, France; Institute of Population Health, Centre for Global Health, and School of Nursing, University of Ottawa, Ottawa, Ontario, Canada; Department of Family Medicine and Emergency Medicine, Université Laval, Québec City, Québec, Canada; Bruyere Research Institute, University of Ottawa, Ottawa, Ontario, Canada; University of Twente, Enschede; VU Medical Centre, Amsterdam, The Netherlands; Department of Medicine, University of Sydney, Institute of Bone and Joint Research; University of Western Sydney, Sydney, Australia; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, University of Copenhagen, Bispebjerg and Frederiksberg Hospitals, Copenhagen, Denmark; Department of Rheumatology, Nîmes University Hospital, Montpellier I University, Nîmes, France; Department of General Internal Medicine, Section of Rheumatology and Clinical Immunology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht University, Maastricht, The Netherlands; Department of Internal Medicine II Rheumatology, Clinical Immunology, Osteology, Physical Therapy and Sports Medicine, Schlosspark-Klinik, Teaching Hospital of the Charité, University Medicine, Berlin, Germany; Rheumatology, Michigan State University College of Human Medic
Objective: Despite the importance of shared decision making for delivering patient-centered care in rheumatology, there is no consensus on how to measure its process and outcomes. The aim of this Outcome Measures in Rheumatology (OMERACT) working group is to determine the core set of domains for measuring shared decision making in intervention studies in adults with osteoarthritis (OA), from the perspectives of patients, health professionals, and researchers.
Methods: We followed the OMERACT Filter 2.
The burden of non-radiographic axial spondyloarthritis.
Semin Arthritis Rheum
April 2015
Pfizer Inc., Collegeville, PA.
Objectives: To identify patients earlier, new classification criteria have been introduced for axial spondyloarthritis (axSpA). Patients who satisfy the clinical or imaging criteria for axSpA in the absence of definite sacroiliac joint changes on pelvic x-rays are classified as having non-radiographic axSpA. Although the burden associated with radiographic axSpA (i.
View Article and Find Full Text PDFUpdating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity.
J Rheumatol
May 2014
From the Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Departments of Epidemiology and Biostatistics, and Rheumatology, VU University Medical Center, Amsterdam, The Netherlands; Versailles-Saint Quentin En Yvelines University, Department of Rheumatology, Ambroise Paré Hospital, APHP, Boulogne-Billancourt; Paris-Descartes University, Medicine Faculty, APHP, Cochin Hospital, Rheumatology B, Paris, France; Department of Occupational Sciences and Occupational Therapy, Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht University, The Netherlands; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA; Section of Rheumatology, Cardiff University School of Medicine, Cardiff, UK; Division of Musculoskeletal Disease, University of Leeds, and the UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, UK; Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Department of Rheumatology, Geffen School of Medicine at the University of California in Los Angeles, Los Angeles, California, USA; Université de Lorraine, EA 4360 APEMAC, Nancy; Université Pierre et Marie Curie (UPMC) - Paris 6, GRC-UMPC 08 (EEMOIS); AP-HP Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Oslo University Hospital and Lovisenberg Diaconal University College, Oslo, Norway; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; University of the West of England, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UK; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Department of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center Heerlen, Heerlen, The
Objective: The Outcome Measures in Rheumatology (OMERACT) Filter provides guidelines for the development and validation of outcome measures for use in clinical research. The "Truth" section of the OMERACT Filter requires that criteria be met to demonstrate that the outcome instrument meets the criteria for content, face, and construct validity.
Methods: Discussion groups critically reviewed a variety of ways in which case studies of current OMERACT Working Groups complied with the Truth component of the Filter and what issues remained to be resolved.
Updating the OMERACT filter: discrimination and feasibility.
J Rheumatol
May 2014
From the Cardiovascular Research Methods Centre, Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Departments of Epidemiology and Biostatistics, and Rheumatology, VU University Medical Center, Amsterdam, The Netherlands; University of Bristol Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UK; Department of Occupational Sciences and Occupational Therapy, Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht University, Maastricht, The Netherlands; Australian Health Workforce Institute (AHWI), School of Population Health, University of Melbourne, Melbourne, Australia; Division of Musculoskeletal Disease, University of Leeds, and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Versailles-Saint Quentin En Yvelines University, Department of Rheumatology, Ambroise Paré Hospital, APHP, Boulogne-Billancourt; Paris-Descartes University, Medicine Faculty, APHP, Cochin Hospital, Rheumatology B, Paris, France; Section of Rheumatology, Cardiff University School of Medicine, Cardiff, UK; Department of Rheumatology, Geffen School of Medicine at the University of California in Los Angeles; Los Angeles, California, USA; Université Pierre et Marie Curie (UPMC) - Paris 6, GRC-UMPC 08 (EEMOIS); AP-HP Pitié Salpêtrière Hospital, Department of Rheumatology, Paris; Université de Lorraine, Université Paris Descartes, Nancy, France; University of Leeds, Section of Musculoskeletal Disease, LIMM Chapel Allerton Hospital, Leeds West Yorkshire; University of the West of England, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UK; Department of Rh
The "Discrimination" part of the OMERACT Filter asks whether a measure discriminates between situations that are of interest. "Feasibility" in the OMERACT Filter encompasses the practical considerations of using an instrument, including its ease of use, time to complete, monetary costs, and interpretability of the question(s) included in the instrument. Both the Discrimination and Reliability parts of the filter have been helpful but were agreed on primarily by consensus of OMERACT participants rather than through explicit evidence-based guidelines.
View Article and Find Full Text PDFEstablishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop.
J Rheumatol
April 2014
From the Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Johns Hopkins University, Baltimore, Maryland, USA; McGill University, Montreal, Quebec, Canada; Schlosspark Klinik, Charité University Medicine, Berlin, Germany; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA; University of the West of England, Bristol, UK; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Musculoskeletal Group, Cochrane Collaboration; University of Sydney Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; National Fathers' Network, Seattle, Washington, USA; Arthritis Research Center, Vancouver, British Columbia, Canada; Tools2use.eu, Bussum, The Netherlands; and the Department of Rheumatology, Cardiff University, Cardiff, UK.
Objective: The OMERACT Rheumatoid Arthritis (RA) Flare Group (FG) is developing a data-driven, patient-inclusive, consensus-based RA flare definition for use in clinical trials, longterm observational studies, and clinical practice. At OMERACT 11, we sought endorsement of a proposed core domain set to measure RA flare.
Methods: Patient and healthcare professional (HCP) qualitative studies, focus groups, and literature review, followed by patient and HCP Delphi exercises including combined Delphi consensus at Outcome Measures in Rheumatology 10 (OMERACT 10), identified potential domains to measure flare.
Toward a generalized framework of core measurement areas in clinical trials: a position paper for OMERACT 11.
J Rheumatol
May 2014
From the Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands; Centre for Global Health Research, Institute of Population Health, University of Ottawa, Ottawa; University of Bristol, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UK; Mobility Program Clinical Research Unit, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Canada; International Classification of Functioning, Disability, and Health (ICF) Research Branch in cooperation with the World Health Organization (WHO) Collaborating Centre for the Family of International Classifications in Germany; Swiss Paraplegic Research (SPF), Nottwil; Department of Health Sciences and Health Policy, University of Lucerne, Lucerne; and at SPF, Nottwil, Switzerland; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands; Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA; Respiratory Unit, Alder Hey Children's Hospital, Liverpool, UK; Department of Medicine, University of Ottawa, Ottawa, Canada.
Objective: The Outcome Measures in Rheumatology (OMERACT) international consensus initiative has successfully developed core sets of outcome measures for trials of many rheumatologic conditions, but its expanding scope called for clarification and updating of its underlying conceptual framework and working process. To develop a core set of what we propose to call outcome measurement instruments, consensus must be reached both on what to measure and how to measure. This article deals with the first part: a framework necessary to ensure comprehensiveness of the domains chosen for measurement.
View Article and Find Full Text PDFThe burden of illness of rheumatoid arthritis.
Clin Rheumatol
March 2011
Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Center and Caphri Research Institute, P Debyelaan 25, 6229 HX, Maastricht, Netherlands.
It is necessary to understand the full burden of illness of a disease before the value of interventions can be assessed. Rheumatoid arthritis (RA) has an impact on a variety of stakeholders, including patients, healthcare systems, and society as a whole. This overview discusses the societal and patient perspectives, distinguishing several domains of impact.
View Article and Find Full Text PDFThe economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis.
Clin Exp Rheumatol
February 2010
Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and Caphri Research Institute, Maastricht, The Netherlands.
During the last decade the economic burden of rheumatic diseases has been increasingly recognised. Even though more studies have been published on rheumatoid arthritis (RA) than ankylosing spondylitis (AS) sufficient data is available for comparison of some economic consequences. This overview addresses mainly the societal impact of RA and AS on (1) labour force participation, on (2) the costs of healthcare consumption and reduced productivity and on (3) health in terms of QALY.
View Article and Find Full Text PDF